1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Vasamed, Inc.

Vasamed, Inc.

VSMD
Vasamed, Inc.US flagOther OTC
0.00
USD
- -
- -
802.00Market Cap
1996 Y
1997 Y
1998 Y
1999 Y
2000 Y
2001 Y
2002 Y
2003 Y
2004 Y
2005 Y
TTM
Revenue per Share
0.17
0.1
0.69
0.09
- -
0.45
0.57
0.67
0.31
0.37
0.52
Basic EPS, GAAP
-7.81
-8.1
-8.04
-5.27
-3.54
-2.24
-0.67
-0.71
-1.85
-1.84
-1.5
Free Cash Flow per Basic Share
-7.72
-9.35
-7.67
-4.36
-2.26
-0.8
-0.88
-0.55
-1.16
-1.32
-1.27
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-29.24
-33.23
-39.64
-44.68
-47.7
-49.26
-27.91
-24.73
-24.59
-24.81
-25.3
Tangible Book Value per Share
25.5
14.15
7.12
1.91
0.28
-0.54
-0.37
0.12
-1.2
0.05
-0.5
Basic Weighted Avg Shares
1
1
1
1
1
2
3
3
3
4
4
Sales/Revenue/Turnover
- -
- -
1
- -
- -
1
2
2
1
1
2
Operating Margin (%)
-5,450
-8,888.14
-1,218.97
-5,874.18
-370,654,600
-396.9
-119.53
-107.68
-588.78
-342.08
-230.76
Depreciation Expense
1
1
1
1
1
- -
- -
- -
- -
- -
1
Net Income, GAAP
-9
-11
-12
-8
-5
-3
-2
-2
-6
-5
-6
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-4,700
-8,041.49
-1,159.85
-5,804.23
-530,217,800
-494.55
-117.63
-107.4
-600.66
-352.61
-279.66
Working Capital
30
18
9
2
- -
-2
-2
- -
-4
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
Total Equity
31
20
11
3
1
- -
- -
1
-4
1
-1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'06
Jun'06
Sep'06
ST Debt
- -
- -
- -
LT Borrowings
1
2
3
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
9
8
6

Working Capital

FRC

•

in mil. unless spec.
Mar'06
Jun'06
Sep'06
Total Current Assets
3
2
2
Cash, Cash Equivalents & STI
2
1
1
Accounts Receivable, Net
- -
- -
- -
Inventories
1
1
1
Total Current Liabilities
1
1
2
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-216.71%
-116.1%
Free Cash Flow
- -
32.05%
21.52%
Net Income, GAAP
- -
19.88%
-23.88%
Sales/Revenue/Turnover
- -
13,750,008.79%
29.66%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2004
- -
- -
- -
- -
1
2005
- -
- -
- -
1
1
2006
- -
- -
1
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2004
-0.32
-0.86
-0.39
- -
-1.85
2005
-0.29
-0.77
-0.53
- -
-1.84
2006
-0.35
-0.44
-0.45
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2004
- -
- -
- -
- -
- -
2005
- -
- -
- -
- -
- -
2006
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Paulita LaPlante
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
7615 Golden Triangle Drive Eden Prairie MN United States of America 55344
IPO Date
Feb 14, 1996
Website
vasamed.com
Similar Companies
Microbot Medical Inc. (MBOT)
Retractable Technologies, Inc. (RVP)
Deltagen Inc. (DGEN)
Ortivus AB (publ) (ORTI-A.ST)
Azenta, Inc. (0HQ1.L)
iRay Technology Company Limited (688301.SS)
Business
Vasamed, Inc. (VSMD) designs, licenses, manufactures, and distributes non-invasive diagnostic products, software, and services for assessing and managing hemodynamic health, with a focus on peripheral arterial disease, wound healing, vascular conditions, and cardiovascular applications. The company offers the SensiLase System for wound healing and peripheral arterial disease assessment; MicroStat pslCO2 for evaluating regional hypoperfusion; AcQtrac System for mechanical cardiodynamic assessment; laser Doppler blood perfusion and perfusion pressure monitors; and fiber optic probes for blood flow monitoring. Vasamed operates primarily in the healthcare equipment industry, targeting clinicians, hospitals, and wound care providers in the United States. Founded in 1988 and headquartered at 7615 Golden Triangle Drive, Suite A, Eden Prairie, Minnesota 55344, Vasamed trades on the OTC Pink Sheets under the ticker VSMD, with approximately 8.01 million shares outstanding and a market capitalization of US$8,000. The company maintains a lean operation with 11-50 employees and provides technical support services alongside its product portfolio. No major acquisitions, funding rounds, partnerships, or strategic shifts have been reported for Vasamed in the last 1-2 years, reflecting stable operations amid a low-profile public listing.

Company News

APIChat

  • defenseworld.net

    Sintx Technologies (NASDAQ:SINT) versus Vasamed (OTCMKTS:VSMD) Critical Review

  • defenseworld.net

    Head-To-Head Survey: Vasamed (OTCMKTS:VSMD) vs. Orthofix Medical (NASDAQ:OFIX)

  • defenseworld.net

    Semler Scientific (NASDAQ:SMLR) & Vasamed (OTCMKTS:VSMD) Head-To-Head Survey

  • defenseworld.net

    Head to Head Review: Hyperfine (NASDAQ:HYPR) vs. Vasamed (OTCMKTS:VSMD)